218. Negro, F, Clement, S, Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C, J of Vir Hep, Oct 2009, 16(10):681-688 219. Su T.C, Chronic hepatitis B virus infection and dyslipidemia, Journ of the Formosan Medical Association, 2004, vol. 103, n o 4, pp. 286-291 220. Deterding K.et al. Gilberts syndrome and antiviral therapy of chronic hepatitis C, Ann of Hepatol, jul-sept, vol8, no3,2009:246-250 221. Cribier B, Urticaria and hepatitis, Clin Rev Allergy Immunol. 2006; 30(1):25-9 222. Vaida GA; Goldman MA; Bloch KJ, Testing for hepatitis B virus in patients with chronic urticaria and angioedema, J Allergy Clin Immunol. 1983; 72(2):193-8 223. Băicuş C., Medicina bazată pe dovezi: Cum <strong>în</strong>ţelegem studiile; Bucureşti Ed.Medicală, 2007:24-37 224. Băicuş C., Dicţionar de epidemiologie clinică şi medicină bazată pe dovezi, Bucureşti, Ed.Medicală 2001:33-36 225. Azoicăi D.,Boiculese L., Pisică-Donose G., Noţiuni de metodologie epidemiologică şi statistică medicală, Iaşi, Ed. Dan, 2001: 22-41 226. Azoicăi D., Ancheta epidemiologică <strong>în</strong> practica medicală, Iaşi, Ed.Polirom, 1998:12-16 227. K Moriya, K Nakagawa, T Santa, Y Shintani, H Fujie, H Miyoshi, T Tsutsumi, T Miyazawa, K Ishibashi, T Horie, K Imai, T Todoroki, S Kimura, K Koike, Oxidative stress in the absence of inf<strong>la</strong>mmation in a mouse model for hepatitis C virus-ass, Cancer Res (2001) 61: 4365-70 228. Tel'nykh IuV, Maevskaia MV, Glushenkov DV, The use of hepatoprotector LiverPro in combined therapy of chronic viral hepatitis C, Klin Med (Mosk). 2008;86(11):60-2 229. M. Nishioka Treatment of interferon non –responder patients with chronic hepatits C in Asia Chronic hepatitis:metabolic,cholestatic,viral and autoimmune ed Duke University MedicalCcenter,Durham , NC,USA 230. Tsubota A, Kumada H, Arase Y et al Combined ursodeoxyicolic acid and glycyrrhizin therapy for chronic hepatitits C virus infection: a randomized controled trial in 170 patients. Eur, J. Gastroeterol Hepatol. 1999; 11: 1077-83 231. Ikeda K, Arase Y, Kobayashi M et. Al. A long- term glycyrrhizin therapy injection reduces hepatocellu<strong>la</strong>r carciongenesis rate in patients with interferon resistant active chronic hepatitis C: a cohort study of 1249 patients. Dig. Dis Sci. 2006; 5; 603-9 232. Choi, J, Ou JHJ, Mechanisms of Liver Injury. III. Oxidative stress in the pathogenesis of hepatitis C virus, Am J of Phys, May 2006, 290(5 ),847-851 233. Abdal<strong>la</strong> MY, Ahmad IM, Spity DR, et al. Hepatitis C virus-core and nonstructural proteins lead to different effects on cellu<strong>la</strong>r antioxidant defenses. J Med Virol. 2005; 76: 489-497 234. Bureau C, Bernard J, Chaouche N, et al. Nonstructral 3 protein hepatitis C virus triggers an oxidative burst in human monocytes via activation of NADPH oxidase. J Biol Chem. 2001; 276: 23077-23083
235. Moriya K, Nakgawa K, Santa T, et al. Oxidative stress in the absence of inf<strong>la</strong>mmation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res. 2001; 61: 4365-4370 236. Okuda M, Li K, Beard MR, et al. Mithocondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology. 2002; 122: 366-375 237. Lenard I, Stresul oxidativ <strong>în</strong> infecţia cu virusul hepatitei C, Teză de doctorat, Conducător ştiinţific Prof. Dr. Spineanu R, UMF Oradea, 2008 238. Jara P.et al, Chronic Hepatitis C Virus Infection in Childhood: Clinical Patterns and Evolution in 224 White Children, Clin Infect Dis. (2003) 36 (3): 275- 280 239. Fonkalsrud E, Myers N.,A, Robinson M,J, Management of Extrahepatic Portal Hypertension in Children, Ann Surg. 1974 Oct; 180(4): 487–491
- Page 1 and 2:
UNIVERSITATEA DE MEDICINĂ ŞI FARM
- Page 3 and 4:
II.2.6 Afectarea neurologică 45 II
- Page 5 and 6:
STADIUL CUNOAŞTERII ACTUALE MANIFE
- Page 7 and 8:
fenomenelor autoimune concomitente.
- Page 9 and 10: Afectarea cerebrală Multe din stud
- Page 11 and 12: cardiomiopatii hipertrofice şi 33,
- Page 13 and 14: fost citată mai ales în America d
- Page 15 and 16: şi complement, dar şi crioprecipi
- Page 17 and 18: sunt secundare hepatopatiilor croni
- Page 19 and 20: PARTEA PERSONALĂ STUDIUL I. MANIFE
- Page 21 and 22: Tabelul.5.III. Distribuţia cazuril
- Page 23 and 24: Fig.5.10. Repartiţia cazurilor în
- Page 25 and 26: Tabelul 5.XXX. Parametrii estimaţi
- Page 27 and 28: Valorile colesterolului în dinamic
- Page 29 and 30: Tabelul 5.LXXXVIII Estimarea parame
- Page 31 and 32: Corelaţie parţială fost calculat
- Page 33 and 34: EVALUAREA CALITĂŢII VIEŢII LA CO
- Page 35 and 36: DISCUŢII 1. Stabilirea tipului, in
- Page 37 and 38: sau dobândită, ar trebui testaţi
- Page 39 and 40: De asemeni, leucopeniile s-au asoci
- Page 41 and 42: la două ore, date care sunt în co
- Page 43 and 44: demonstrează o asociere moderată
- Page 45 and 46: CONCLUZII 1. Profilul pacientului p
- Page 47 and 48: 26. Exacerbarea manifestărilor aut
- Page 49 and 50: 34. Iashina TL, Favorov MO, Shakhgi
- Page 51 and 52: 66. Zuckerman J, van Hattum J, Caff
- Page 53 and 54: 99. Gish G. R., et al, Safety and a
- Page 55 and 56: 134. Simsek H, Savas C, Akkiz H, Te
- Page 57 and 58: 167. Quaranta JF, Tran A, Regnier D
- Page 59: 201. Trepo C, Guillevin L, Polyarte